Vis Marijn, Nurmohamed Michael T, Wolbink Gertjan, Voskuyl Alexandre E, de Koning Margret, van de Stadt Rob, Twisk Jos W R, Dijkmans Ben A C, Lems Willem F
Department of Rheumatology, VU University Medical Centre, Jan van Breemen Institute, Amsterdam, The Netherlands.
J Rheumatol. 2005 Feb;32(2):252-5.
Cardiovascular morbidity and mortality appear to be enhanced in rheumatoid arthritis (RA), which might be due to an increased prevalence of cardiovascular risk factors such as dyslipidemia. It was recently shown that effective disease modifying antirheumatic drug treatment had a favorable influence on the lipid profile in patients with active RA. As infliximab markedly reduces disease activity in RA, we investigated the effects of infliximab on the lipid profile.
Infliximab was administered at baseline and at 2 and 6 weeks in patients with active RA. Total cholesterol and HDL-cholesterol concentrations were measured and their ratio, the atherogenic index (an important cardiovascular risk factor indicator), was assessed.
Sixty-nine patients were enrolled. The Disease Activity Index score (DAS-28) was 5.9 (SD +/- 1.4) at baseline and decreased to 4.6 (+/- 1.4) after 2 weeks and further to 4.1 (+/- 1.5) after 6 weeks. Total cholesterol level was 5.2 mmol/l at baseline and increased to 5.7 mmol/l (p < 0.001) at 2 weeks, and was 5.6 mmol/l (p < 0.001 vs baseline) at Week 6. For HDL-cholesterol these values were 1.5, 1.6 (p < 0.001), and 1.6 mmol/l (p < 0.001 vs baseline), respectively. Changes in disease activity were significantly inversely associated with changes in total cholesterol and HDL-cholesterol levels. The atherogenic index, however, remained constant. Corticosteroid use at baseline was associated with significantly higher total cholesterol and HDL-cholesterol levels and a lower (more favorable) atherogenic index at baseline.
Infliximab treatment was associated with a significant increase of both total cholesterol and HDL-cholesterol levels, which correlated with decreasing disease activity. However, this was not accompanied by a favorable effect on the atherogenic index. The favorable effect of infliximab on cardiovascular comorbidity might not be mediated by effects on lipid metabolism, but longterm investigations are needed to confirm this.
类风湿关节炎(RA)患者心血管疾病的发病率和死亡率似乎有所增加,这可能是由于血脂异常等心血管危险因素的患病率上升所致。最近有研究表明,有效的改善病情抗风湿药物治疗对活动期RA患者的血脂状况有积极影响。由于英夫利昔单抗能显著降低RA的疾病活动度,我们研究了英夫利昔单抗对血脂状况的影响。
对活动期RA患者在基线、第2周和第6周给予英夫利昔单抗治疗。测量总胆固醇和高密度脂蛋白胆固醇浓度,并评估它们的比值即致动脉粥样硬化指数(一个重要的心血管危险因素指标)。
共纳入69例患者。疾病活动指数评分(DAS-28)在基线时为5.9(标准差±1.4),2周后降至4.6(±1.4),6周后进一步降至4.1(±1.5)。总胆固醇水平在基线时为5.2 mmol/L,2周时升至5.7 mmol/L(p<0.001),第6周时为5.6 mmol/L(与基线相比p<0.001)。高密度脂蛋白胆固醇的相应值分别为1.5、1.6(p<0.001)和1.6 mmol/L(与基线相比p<0.001)。疾病活动度的变化与总胆固醇和高密度脂蛋白胆固醇水平的变化显著负相关。然而,致动脉粥样硬化指数保持不变。基线时使用皮质类固醇与总胆固醇和高密度脂蛋白胆固醇水平显著升高以及基线时较低(更有利)的致动脉粥样硬化指数相关。
英夫利昔单抗治疗与总胆固醇和高密度脂蛋白胆固醇水平显著升高相关,这与疾病活动度降低相关。然而,这并未对致动脉粥样硬化指数产生有利影响。英夫利昔单抗对心血管合并症的有利影响可能不是通过对脂质代谢的作用介导的,但需要长期研究来证实这一点。